Functional avoidance‐based intensity modulated proton therapy with 4DCT derived ventilation imaging for lung cancer. Issue 7 (22nd June 2021)

• Record Type: Journal Article
• Authors: Dougherty, Jingjing M.; Castillo, Edward; Castillo, Richard; Faught, Austin M.; Pepin, Mark; Park, Sean S.; Beltran, Chris J.; Guerrero, Thomas; Grills, Inga; Vinogradskiy, Yevgeniy
• Is Part Of: Journal of applied clinical medical physics. Volume 22:Issue 7(2021)
• Page Start: 276
• Page End: 285
• Publication Date: 2021-06-22
• Subjects: 4DCT -- functional lung imaging -- IMPT -- lung toxicity -- lung ventilation -- proton motion interplay -- proton therapy -- radiation pneumonitis; Medical physics -- Periodicals; Clinical medicine -- Periodicals; Health Physics; Clinical Medicine; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; 610.153
• DOI: 10.1002/acm2.13323
• Languages: English
• ISSNs: 1526-9914

Abstract

Abstract: The primary objective is to evaluate the potential dosimetric gains of performing functional avoidance‐based proton treatment planning using 4DCT derived ventilation imaging. 4DCT data of 31 patients from a prospective functional avoidance clinical trial were evaluated with intensity modulated proton therapy (IMPT) plans and compared with clinical volumetric modulated arc therapy (VMAT) plans. Dosimetric parameters were compared between standard and functional plans with IMPT and VMAT with one‐way analysis of variance and post hoc paired student t‐test. Normal Tissue Complication Probability (NTCP) models were employed to estimate the risk of two toxicity endpoints for healthy lung tissues. Dose degradation due to proton motion interplay effect was evaluated. Functional IMPT plans led to significant dose reduction to functional lung structures when compared with functional VMAT without significant dose increase to Organ at Risk (OAR) structures. When interplay effect is considered, no significant dose degradation was observed for the OARs or the clinical target volume (CTV) volumes for functional IMPT. Using fV20 as the dose metric and Grade 2+ pneumonitis as toxicity endpoint, there is a mean 5.7% reduction in Grade 2+ RP with the functional IMPT and as high as 26% in reduction for individual patient when compared to the standard IMPT planning. Functional IMPT was able to spare healthy lung tissue to avoid excess dose to normal structures while maintaining satisfying target coverage. NTCP calculation also shows that the risk of pulmonary complications can be further reduced with functional based IMPT.